Insmed (NASDAQ:INSM) Rating Lowered to Sell at StockNews.com

Insmed (NASDAQ:INSM) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

Other research analysts have also issued research reports about the stock. UBS Group assumed coverage on shares of Insmed in a research note on Tuesday, February 27th. They issued a “buy” rating and a $46.00 price target on the stock. Wells Fargo & Company reiterated an “overweight” rating and issued a $55.00 price target on shares of Insmed in a research note on Monday, April 1st. Truist Financial initiated coverage on shares of Insmed in a research report on Tuesday, April 23rd. They set a “buy” rating and a $48.00 target price on the stock. Guggenheim increased their target price on shares of Insmed from $52.00 to $54.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, Barclays increased their target price on shares of Insmed from $37.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 11th. One equities research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $44.92.

Insmed Stock Up 0.5 %

Shares of NASDAQ INSM opened at $26.08 on Monday. The company’s fifty day moving average is $26.65 and its 200-day moving average is $27.08. The stock has a market cap of $3.87 billion, a price-to-earnings ratio of -4.88 and a beta of 0.93. Insmed has a twelve month low of $18.08 and a twelve month high of $32.00.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($1.13) by ($0.15). The business had revenue of $83.70 million for the quarter, compared to analysts’ expectations of $82.15 million. Insmed’s quarterly revenue was up 41.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.20) earnings per share. On average, research analysts anticipate that Insmed will post -4.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Susquehanna Fundamental Investments LLC bought a new position in shares of Insmed during the first quarter valued at about $4,515,000. SG Americas Securities LLC raised its position in Insmed by 123.1% in the first quarter. SG Americas Securities LLC now owns 8,508 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 4,695 shares during the period. Essex Investment Management Co. LLC raised its position in Insmed by 0.6% in the first quarter. Essex Investment Management Co. LLC now owns 108,629 shares of the biopharmaceutical company’s stock worth $2,947,000 after acquiring an additional 622 shares during the period. Fidelis Capital Partners LLC bought a new stake in Insmed in the first quarter worth about $34,000. Finally, Principal Financial Group Inc. raised its position in Insmed by 5.9% in the first quarter. Principal Financial Group Inc. now owns 1,439,280 shares of the biopharmaceutical company’s stock worth $39,048,000 after acquiring an additional 79,717 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.